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Background: Genomic, proteomic and high-throughput gene expression data, when integrated, can be used to
map the interaction networks between genes and proteins. Different approaches have been used to analyze these
networks, especially in cancer, where mutations in biologically related genes that encode mutually interacting
proteins are believed to be involved. This system of integrated networks as a whole exhibits emergent biological
properties that are not obvious at the individual network level. We analyze the system in terms of modules, namely
a set of densely interconnected nodes that can be further divided into submodules that are expected to participate
in multiple biological activities in coordinated manner.
Results: In the present work we construct two layers of the breast cancer network: the gene layer, where the
correlation network of breast cancer genes is analyzed to identify gene modules, and the protein layer, where each
gene module is extended to map out the network of expressed proteins and their interactions in order to identify
submodules. Each module and its associated submodules are analyzed to test the robustness of their topological
distribution. The constituent biological phenomena are explored through the use of the Gene Ontology. We thus
construct a “network of networks”, and demonstrate that both the gene and protein interaction networks are
modular in nature. By focusing on the ontological classification, we are able to determine the entire GO profiles
that are distributed at different levels of hierarchy. Within each submodule most of the proteins are biologically
correlated, and participate in groups of distinct biological activities.
Conclusions: The present approach is an effective method for discovering coherent gene modules and protein
submodules. We show that this also provides a means of determining biological pathways (both novel and as well
those that have been reported previously) that are related, in the present instance, to breast cancer. Similar
strategies are likely to be useful in the analysis of other diseases as well.
Keywords: Protein-protein interaction, Gene expression, Networks, Modules, Gene ontologyBackground
The current paradigm in a systems approach to bio-
logical phenomena is that of networks and the interac-
tions among them. Advances in genomic, proteomic and
high-throughput gene expression data, when integrated,
can be used to map the interaction networks between
genes and proteins, as well as their association with spe-
cific biological activities. It has also become increasingly
clear that an integrated analysis of these extensive com-
ponents is crucial, especially in the case of cancers [1].* Correspondence: foralok@gmail.com; r.ramaswamy@gmail.com
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unless otherwise stated.Mutation in biologically correlated genes affects the
translation of key proteins that do not function in
isolation: distinct biological activities are the result of
the coordinated action of multiple proteins [2] and a
reduction in the synthesis of one protein can directly
affect various specialized biological actions.
In the case of breast cancer for example, the interaction
network of 6004 proteins is, in different combinations,
associated with 5732 biological processes (BP), 1930 mo-
lecular functions (MF) and 879 cellular components (CC)
as specified in the Gene Ontology Annotation (GOA) [3]
database. On this scale it is difficult to interpret the
organization principle of such networks that may beral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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more highly connected subunits participate in multiple
biological activities [4].
The alternative bottom-up approach, namely breaking
up the complex network into several interacting sub-
networks, can be more helpful. These sub-networks help
to analyse the activity at various levels of specificity,
especially in case of complex diseases where the main
interest is to elucidate the coordination principle that
controls the progression of the disease.
The modular nature of a wide variety of complex
networks has been investigated in detail in recent years,
ranging from social networks [5], cellular phone net-
works [6], collaboration networks [7], citation networks
[8], gene co-occurrence network [9], protein-protein
interaction (PPI) networks [10], and metabolic networks
[10]. A module can be defined as a subset of the nodes
such that nodes within the module are densely con-
nected while being sparsely connected with nodes in
other modules [11]. Modules are the building blocks of
higher-level functional organization, and can exhibit
hierarchical properties. In particular, modules can be
recursively divided into smaller submodules; such sub-
modules are potentially a rich source of information on
biological networks [12-15]. Nodes within a submodule
are more likely to have closely related biological proper-
ties, and thus separating a network into modules and sub-
modules can make it possible to understand the moreFigure 1 Schematic diagram representing two-layer network structur
layer. Each dotted hull shows an individual gene module of connected gen
the protein layer to construct a primary network of expressed proteins, shown
green. Each solid hull represents the protein module corresponding to the ge
accompanying flow-chart gives an overview of the protocol.specific domain of activities in which they participate,
either singly or in a coordinated manner. (By domain
we mean here the specializations defined by Gene
Ontology (GO) [16], namely BP, MF or CC.)
In the present paper we propose a general framework
for the analysis of breast cancer data. By combining
information on correlated genes and knowledge of their
associated proteins, it is possible to construct a model
two-layer network that can be explored to uncover the
underlying biological phenomena in cancers. Analyzing
the network as a whole gives insight into all annotated
biological activities and specific sub-activities within
the cell. On the gene layer we construct a correlation
network from the expression data available for disease
specific genes using Graphical Gaussian Modeling (GGM)
[17]. The corresponding protein layer is constructed from
the known set of proteins expressed by each of the genes
to make the primary network, and a secondary network
that shows their corresponding interactions is constructed
from available protein interaction data. This two layer
analysis is schematically shown in Figure 1. On each
layer, modules are identified through a fast greedy
optimization algorithm [18] applied recursively. We also
investigate the robustness of the various modules by
examining the effect of node removal. Each protein sub-
module is further divided into an inter-modular bridge
class and an intra-modular group class, so as to identify
the domains with the largest number of participatinge between genes and proteins. Nodes are coloured red in the gene
es, based on their co-expression correlations. This is projected onto
in blue. The secondary network of interacting proteins is highlighted in
ne module. Protein submodules are shown within these modules. The








KEGG 9 9 Jan, 2010 (V-53) WGS
CGC 19 20 Apr, 2011 LC
BCGD 62 62 1999 LC
TGDB 67 67 1999 LC
CGAP 69 69 Jan, 2010 GE
CGW 82 83 ApR, 2003 LC
NCG 140 144 Jun, 2011 (V-2.1) HTMS
GAD 695 690 Jun, 2011 LC
Total 975 956
WGS, Whole genome sequencing; LC, Literature curation; GE, Gene Expression;
HTMS, High throughput mutational screening; V, Version;
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in effect to construct a network of networks and to
examine the connections between the different domain
groups within the protein submodules.
There are several methods that can be used to detect
modularity, and a number of algorithms have been de-
scribed [10,18-24]. In our study we focus on the gene
module and protein submodule detection using a fast
greedy modularity optimization technique [18] that is
efficient in the analysis of large networks. The detailed
topology of the submodules is interesting: the group of
proteins within a submodule that interact physically with
other proteins tend to form two sorts of hubs. The so
called ‘party hubs’ interact with most (or all) of their
partners simultaneously, while ‘date hubs’ are those that
interact with different partners at different times [25].
Party hubs are intra-modular and the constituent pro-
teins are believed to perform a specific biological activity
within the submodule. In contrast, the activity of date
hubs is intermodular and link different biological do-
mains [26]. Proteins belonging to each hub within a sub-
module can be further explored from an ontological
perspective: a group of proteins can be located in one or
more cellular component, be active in one or more bio-
logical processes, and perform one or more molecular
functions, but since domain activity is shared by several
(and overlapping) groups, classification using GO terms
can become very complex. This can be reduced to some
extent by the implementation of a majority rule or by
GO homogeneity (GO-H) analysis [27]. In the present
case we use this latter reduction to identify GO terms
associated with the largest fraction of proteins within a
given hub class (i.e. party or date).
A domain cluster is a group of three or more GO
terms connected together by a parent–child relationship,
namely these form a directed acyclic graph (DAG) [16].
GO terms up to the 2nd level is general while terms
at the lower levels are specific, and we explored the
biological domain cluster of similar GO terms through
OntoVisT [28], a general purpose tool developed earlier
for interactive visualization and navigation of any ontology.
We present our findings using a exhaustive list of
breast cancer genes, proteins and their PPI network
from the Human Protein Reference Database (HPRD)
[29] in combination with the comprehensive and well-
established microarray datasets from breast cancer
patients [30,31].
Methods
Materials: breast cancer data
We have integrated nine cancer resources in order to
obtain a comprehensive list of breast cancer marker
genes. The different resources focus on different aspects
of biology: NCG (Network of Cancer Genes) has data on gene
mutations [32],
 TGDBs (Tumor Gene Family of Databases) lists the
target genes implicated in cancer-causing mutations
[33],
 CGW (Cancer Genetics Web) details primary
mutations that cause cancer, as well as secondary
genetic abnormalities caused by cancer [34],
 CGC (Cancer Gene Census) catalogues all genes
whose mutations have been implicated in cancer [35],
 KEGG (Kyoto Encyclopedia of Genes and Genomes)
integrates current knowledge on molecular
interaction networks [36],
 BCGD (Breast Cancer Gene Database) collects
molecular genetic data related to genes involved in
breast cancer [37],
 CGAP (Cancer Genome Anatomy Project) lists gene
expression profiles of cancer cells [38],
 OMIM (Online Mendelian Inheritance in Man) is a
compendium of information on genetic disorders
and genes [39], and
 GAD (Genetic Association Database) contains genetic
association study data reported in the literature [40].
From the above integrated sources we identified 975
breast cancer genes of which 956 are unique (since some
genes have more than one identifier [41]). This is a more
exhaustive list than what has been hitherto available, and
is summarized in Table 1. Details of the complete marker
gene list are available in Additional file 1: Table S1.
Gene expression microarray data
We use the comprehensive and well curated microarray
data sets first studied by West et al. [30] and Gyorffy
et al. [31], using UniProt [41] in order to convert syn-
onymous gene symbols to their current approved labels.
These datasets are termed Set 1 and Set 2 respectively
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missing values were discarded, and the standard K nearest
neighbor (KNN) imputation technique [42] with k = 10
was used to estimate the missing values in the other
samples. Imputed data was then averaged over all rep-
licates to obtain a processed data matrix; the first data-
set thus contains 49 breast tumor samples separated
into two classes: 25 positive samples for estrogen re-
ceptor (ER+) and 24 negative (ER-) with expression
levels measured for 5728 genes. The second dataset
has 1809 breast tumor samples separated into three
classes: 295 HER2+ samples, 1285 ER+/HER2- sam-
ples, and 229 ER-/HER2- samples with expression
levels measured for 12496 genes. The normalized ex-
pression for the ESR1 gene (Affymetrix ID 205225) at
above 500 is considered as ER+, while ERBB2 gene
(Affymetrix ID 216836_s) above 4800 is regarded as
HER2+ [31].Gene-protein association and protein-protein interaction
data
In order to construct the primary network of expressed
proteins we map genes to the UniProt (July 2011) data-
set [41] that lists 41149 proteins expressed by 19511
genes. The primary network is further extended to form
a secondary network of interacting proteins using HPRD
(Release 9, Aug 2011) [29]. This database has two classes
of interaction data: binary (if two proteins interact dir-
ectly) and complex (when several proteins form a com-
plex). Since protein complexes also constitute functional
groups and take part in activation or inhibition [43] we
also included these complexes in our study with the
assumption that all proteins in a complex interact with
each other. There are a total of 91029 binary interactions
between 13494 proteins and 1521 protein complexes
that are associated with 3652 proteins. On combining
both, we obtain 13691 proteins, with a total of 110613
interactions.Gene ontology annotation data
GO data was used to explore the biological activity of a
group of proteins, by analyzing the molecular func-
tions (MFs) which they perform, the biological pro-
cesses (BPs) in which they participate and their cellular
components. The ontology consists of over thirty thou-
sand terms distributed across 12 different levels of
hierarchy, starting from generic terms at the highest
level, to more specific terms at the leaf nodes. To
incorporate the biological domain knowledge to the
entire groups of proteins, we used GOA data (July 2011)
[3] and found that the 40422 proteins are mapped
to 7488 GO:BP terms, 3221 GO:MF terms, and 1053
GO:CC terms respectively.Methods
Gene network using graphical Gaussian modeling
Microarray data for the integrated set of breast cancer
genes from different resources were used to construct
the gene-gene interaction network based on graphical
Gaussian modeling (GGM) [17]. The false discovery
rate (FDR) criterion is then chosen to filter out the
least significant genes, thus providing a computa-
tional criterion that permits us to determine which
edge is to be included in the network. To construct
the gene network based on the GGM algorithm, we
used the Gene Net algorithm that is included in the R
package [44].
Modularity optimization using fast greedy technique
The gene network is further analyzed to identify mod-
ules using the CNM fast greedy optimization technique
[18]; this identifies a subset of nodes that are densely
connected within modules while being sparsely con-
nected to nodes in other modules. We use the igraph
implementation contained in the R package [45] to
identify gene modules and protein submodules.
Leave-one-out cross-validation (LOO-CV) and majority-
voting technique
To test the robustness of the modular structure obtained
above, we implemented the standard (but computation-
ally expensive) LOO-CV technique by removing a node
and its corresponding interactions from the data to
predict the changed module distribution. The process
is repeated iteratively for each node in the complete
network, and majority voting is then used to identify
the most robust modules.
Protein network construction
Each gene module is projected onto the protein layer in
order to construct the primary network of expressed
proteins and further extended to include the secondary
network of interacting proteins. Combining both pri-
mary and secondary network components gives the
two-layer network shown in Figure 1. Each protein
module is then further analyzed to identify the submo-
dules, using the CNM algorithm along with LOO cross
validation.
Each protein submodule obtained above is divided into
bridge (B) and group (G) hub classes, and further ana-
lyzed using GO homogeneity (GO-H) to identify the
domain groups of those proteins that have a majority
participation in specific GO categories.
GO analysis
For a group of proteins contained in a hub class of
submodule i, GO Homogeneity (GO-H), is defined as a
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among all the mapped GO terms.
GO-Hi =maxj [n
j
i/ni] = maxj [GO h
j
i ]
where ni is the number of proteins in the group i that
have any GO annotations, and nji the number of pro-
teins that have a specific GO term j. GOhji represents
fraction of protein contained in group j. After assigning
nji proteins to a GO term j, ni - n
j
i proteins still remain
and these may participate in other groups. This is done
iteratively for the complete list as shown in Figure 2 so
as to assign GO terms as well as group labels to all the
remaining proteins.
Unannotated proteins introduce errors when included
in GO-H analysis, and are therefore removed from the
list. In order to identify the domain cluster represented
by a group of GO terms we use OntoVisT [28] which
as mentioned above, is a general purpose ontological
visualization tool.
Results
As indicated in the Materials section we combined 9
different cancer resources to get 956 breast cancer
marker genes, of which 610 and 840 genes were found
to be present in Sets 1 and 2 respectively. These are
then used to construct the gene layer networks for
detailed analysis.
Gene layer construction and analysis of gene modules
We construct a partial correlation based gene network
using the GGM technique. For each edge the partial
correlation (pcor), p-value (pval), FDR (qval) and cor-
responding posterior probabilities (prob) are calcu-
lated, and the FDR criterion is employed to assess itsFigure 2 Domain analysis for each hub class of protein submodule. (a
representation of several groups of proteins, and (c) the Pseudocode fo
the fraction of protein contained in a GO term, b defines term < 2nd lev
by a GO group.significance. Table 2 summarizes the information
regarding the gene layer network. The sparse nature of
these networks with a fairly low number of genes
results in a low modularity score Qmax, for the optimal
partitions.
For Set 1 a total of 4619 edges are found with a signifi-
cance level of 30% FDR among the 513 genes (complete
data given in Additional file 2: Table S2). The data was
further stratified into ER + and ER- subtypes, and the
same analysis was carried out (see Additional file 2:
Tables S2). For Set 2, there were a total of 3488 edges
at the same significance among the 796 genes (see
Additional file 3: Table S3), and the samples in Set 2 were
stratified into the three subtypes HER2+, ER+/HER2- and
ER-HER2- as discussed in the Materials and Methods
section. The analysis for the stratified samples gives the
result presented in Table 2.
The networks and modules that result from the
present analysis are consistent across stratification with
some variation. Consider Set 1. When all the samples
are taken together, we find 7 modules with a modularity
score of 0.25. Most of the genes are included in both
the ER + and ER- sample networks, and the results for
the subtypes share a high similarity (86% and 74%,
respectively) with the results for the total sample set.
The number of modules for ER- is slightly larger and
may indicate an increased heterogeneity of the subtype,
but the modules themselves are quite similar.
In Set 2, stratification again gives results that are fairly
consistent, with the number of genes being nearly con-
stant across the subtypes. The number of modules varies
although the similarity measure again gives a high level
of concordance between the modules obtained by con-
sidering the entire sample set and the subtypes (87%,
83% and 88% respectively).) Schematic of the group of proteins, (b) the GO domain
r assigning GO description to a given protein list;. a defined as
el and GO-H represent the max fraction of protein represented
Table 2 Summary of gene layer network for both datasets of breast cancer genes
Set 1: West et al. [30] Set 2: Gyorffy et al. [31]
All samples ER+ ER- ALL samples HER2+ ER+/HER2 ER-/HER2-
Number of samples 49 25 24 1809 295 1285 229
Number of genes 610 610 610 796 796 796 796
λ 0.80 0.81 0.83 0.03 0.14 0.04 0.18
qval 0.30 0.30 0.30 0.30 0.30 0.30 0.30
Genes 513 464 459 796 791 789 793
Number of interactions 4619 5718 1960 3488 6086 2745 7546
α 1.23 1.37 1.38 1.35 1.25 1.40 1.21
Qmax 0.25 0.19 0.47 0.35 0.23 0.39 0.23
Number of modules 7 7 10 10 7 11 6
% accuracy, LOO-CV 78 71 60 57 61 76 72
Similarity measure 86 74 87 83 88
λ, optimal shrinkage intensity; qval, cut off for the partial correlation (the threshold is adjusted so as to ensure that all well-studied breast cancer marker genes are
included in the networks); α, power-law exponent; Qmax, maximum modularity score; LOO-CV, Leave-one-out cross-validation.
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voting) indicate that overall, 78% of the modular struc-
ture remains intact for Set 1 (71% for the ER + subtype
and 60% for ER-) while only 57% is preserved for Set 2
(and correspondingly 61% for HER2+, 76% for ER+/HER2-,
and 72% for ER-/HER2-). See Table 2. Some mismatch
might be expected due to the removal of hubs or some
other important nodes from the network, but on the whole,
these results reliably show that the breast cancer gene
network is modular in nature.
Protein layer construction and analysis of protein
submodules
Modules that are identified in the gene layer for entire
sample set are mapped to their expressed proteins. This
gives the primary protein network, and the secondary
network is then constructed by examining all proteins
that interact with the primary network. Both networks
when combined give the protein module that corre-
sponds to each gene module. Together this forms the
protein layer, as explained in Figure 1. We remove loops
and multiple edges prior to application of the CNM
algorithm to obtain submodules in the protein layer.
Our results for Set 1 are summarized in Table 3. There
are 7 protein modules, each corresponding to a gene
module and these are numbered by rank. The degree
distribution of the networks in each protein module
follows a power-law, with exponents between 1.5 and
1.8. The protein modules are much larger than the
corresponding gene modules and these also have a high
interaction density (namely the number of interactions per
module). Qmax. varies from 0.632 for module 3 which has
a large number of proteins and correspondingly the
most interactions, to 0.798 for module 6, a sparse graphof relatively fewer proteins. Qmax is inversely correlated
to the number of protein-protein interactions. Module
7 has only 7 genes associated with a sparse graph of 113
interactions among 114 proteins. Redoing our analysis
using LOO-CV suggests that more than 86% of the
sub-modular structure is robust. The smallest modules,
6 and 7 give the same submodule structure regardless of
which nodes are left out. These modules are very sparse
and do not contain any hubs. In the larger modules
where there are hubs, removal of such a node can give
very different submodules although the average Qmax
value does not change significantly, indicating that modu-
larity is a robust property.
Set 2 when similarly analysed (see Additional file 4:
Table S4) gives 10 protein modules with similar power-
law distribution in degree, with exponent in the same
range, 1.58-1.75. The Qmax value shows larger variation,
from 0.62 to 0.87, and the number of submodules vary
from 10 to 40 with considerable inter-module linkage. In
other aspects such as modularity robustness, this dataset
is similar to Set 1.
The biological properties of submodules
Proteins in each submodule can be divided into two
classes: group proteins (G) that form so—called party
hubs that interact primarily with other proteins within
the same submodule, and bridge proteins (B) which are
the “date” hubs that interact with proteins in two or
more submodules. Their associated domain properties
are obtained by first mapping them to the GOA [3]
followed by GO-H analysis. Generic GO terms are
discarded up to the second level in the hierarchy, as
also terms with fewer than three proteins. Each domain
group of a submodule class is identified by a group
Table 3 Summary of topological and biological analysis of gene module and their corresponding protein modules for
Set 1
Module Id 1 2 3 4 5 6 7 #U Sum
Topological analysis
Genes 142 142 125 40 35 22 7 513
Expressed proteins 640 486 439 159 152 79 10 1958
PPI 7465 6576 8163 2106 1317 885 126 24752
Processed protein in PPI 3284 3206 3187 1338 797 575 114 6519
Processed PPI 6951 6095 7712 1985 1250 794 113 23173
α 1.606 1.632 1.576 1.701 1.658 1.698 1.777
Qmax 0.637 0.662 0.632 0.714 0.792 0.798 0.793
Modules (Isolated modules) 309 (7) 259 (4) 28 (11) 26 (10) 23 (8) 17 (7) 6 (4) 155 (51)
%age accuracy, LOO-CV 86.510 87.410 95.199 99.028 99.624 100 100
Avg. Qmax, LOO-CV 0.639 0.664 0.634 0.714 0.797 0.797 0.791
Module range, LOO-CV 24-33 20-28 24-34 25-32 21-25 16-18 5-6
Avg. Modules, LOO-CV 28 26 28 26 22 16 5
Biological analysis
GO:BP, Groups 137 135 111 71 45 34 6 539
GO:BP, Terms 96 117 96 67 47 37 8 205
GO:BP, Referenced 42 54 46 32 25 19 8 85
GO:MF, Groups 131 124 115 69 44 35 7 525
GO:MF, Terms 79 72 72 51 33 30 10 145
GO:MF, Referenced 55 40 43 34 24 23 8 91
GO:CC, Groups 112 95 92 55 42 32 6 434
GO:CC, Terms 15 14 14 11 10 13 6 23
GO:CC, Referenced 12 11 12 9 8 9 6 16
Topological analysis represents the analysis of network topology, while biological analysis represents the domain analysis of individual modules; Genes, Number
of genes; Expressed Proteins, Proteins expressed by genes in module; PPI, Number of interaction between proteins; Processed protein in PPI, Number of proteins
after removing loops and multiple edges; Processed PPI, Number of interaction in processed PPI; α, Power law exponent; Qmax, maximum modularity score;
LOO-CV, Leave-one-out cross-validation; Avg. modules, Mean number of modules in LOO-CV; GO:BP, GO:MF, GO:CC represent the GO biological process, GO
molecular function, GO cellular component respectively, while Groups represents the domain groups annotated with each module, Terms represent the unique
number of GO term; and Referenced represents GO terms previously reported in literature, #U Sum, Unique sum.
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a.b.c, with a representing the module ID, b the submo-
dule ID and c the domain ID assigned by our algo-
rithm.The pseudocode is given above (see Figure 2).
Each group ID is also associated with a group label G, B,
OG or OB representing group, bridge, overlapping groups
or overlapping bridges, based on their topological class
category. To identify clusters represented by a given set of
GO terms we use OntoVisT [28]; PUBMED is also queried
in order to determine whether the GO term in the submo-
dule has been previously reported as occurring in any
breast cancer related study.
Both datasets are studied in order to infer the bio-
logical activity for different hub classes of each submo-
dule. The three GO categories BP, MF, and CC are
separately analyzed. The detailed analysis of the main
cluster of each GO category in Set 1 is presented here,
and results for the other clusters of both sets are pro-
vided in the supplementary information.Analysis of molecular functions
The two layer network deduced from the functional ana-
lysis of breast cancer genes found in Set 1 is shown in
Figure 3. The inner circle depicts a coarse-grained image
of the 7 modules in the gene layer. Details of the gene
module and the protein submodules have been discussed
above, and these are summarized in Table 3. The outer
circle represents the protein layer, each sector represent-
ing the corresponding protein modules. Using HPRD
[29] we have identified 23173 distinct protein-protein
(PP) interactions in the network of 6519 proteins that
are divided into 7 modules and 155 distinct submodules
of which 51 are isolated. The interaction network in
each sector shows the submodular network of the func-
tional groups; these are highlighted in different colors.
Each submodule is divided into group and bridge cat-
egories, based on their hub property, and these are then
further analyzed for their functional associations using
GO-H scores. Generic GO terms up to the second level
Figure 3 Two layer network analysis of GO:MF for West dataset. Inner circle shows the coarse grained gene modules while each of the outer
sector represent the protein module corresponding to each gene module. Each submodule in the protein module is highlighted by different color and
three digit number indicates the functional class description of each group of proteins. Functional clusters are shown in the right, contains function id
(#Id), GO term followed by the depth in the GO hierarchy in brackets, number of groups (#G), and also number of proteins (#P) contained in each
specific GO:MF term. First term in each cluster represents the cluster description. Detailed description of each cluster is discussed in the bottom panel.
Disc, ring, and rhombus represents, GO:MF terms have already been reported in literature, newly reported GO terms and cluster component not reported
in our analysis (shown with symbol ‘+’), respectively.
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sponding to fewer than three proteins. This results in
525 different functional groups that participate in 145
GO:MF terms (see Table 3). Each functional group cat-
egory is marked with three digit identifier as discussed,
and the details are included in Additional file 5: Table S5.
As can be seen in Figure 3, namely the cluster diagram,
there are 73 GO:MF terms from 13 different functional
clusters. Among these, the term “Receptor binding” gives
the largest cluster. There are 15 terms in panel C1 and
several of these have been reported in earlier breast cancer
studies. For illustrative purposes, some of these are
discussed briefly below.
For instance, thioredoxin, a redox protein with growth
factor activity (F2++) increases cell proliferation of breast
cancer cells [46]. Many cell line models have been used
to identify genetic elements that mediate the progression
of breast cancer, both hormone dependent as well as
hormone independent metastatic growth [47]. Integrin
binding (F4) plays a crucial role in breast cancer tumor
growth and metastasis [48]. EGFR binding (F10) is me-
diated through the binding of a mitogenic peptide
epidermal growth factor (EGF) to a surface membrane
receptor, EGFR of breast cancer cells [49]. Down-
regulation of Interleukin-6 and its receptor (F11) re-
sults in growth inhibition of MCF-7 breast cancer cells
[50], while high affinity of Insulin receptor binding (F7)
has been observed in the same cells [51]. TGFβR bind-
ing (F9) regulates insulin-like growth factor binding
protein (F5) (IGFBP)-3 production, which is a major
antiproliferative factor and a key element for TGFβ-
induced growth inhibition in breast cancer cells [52].
The breast cancer suppressor gene tyrosine kinase
(PTKs) (F13) is involved in TNF-activated receptor
activity by interacting with ‘TNF receptor-associated
factor interacting protein’ (TRIP) in breast epithelial
cells [53]. ER binding (F15) profiles are used to predict
breast cancer outcome [54]. In some cases, breast
cancer survivals shows elevation in the serum marker
associated with proinflammatory cytokine activity (F8)
[55], while more specific studies suggests that estrogen
exposure decreases chemokine activity (F14), increas-
ing the chance of developing breast cancer [56].
The present protocol also suggests that MHC class I
protein binding as well as notch binding, both of which
have hitherto not been studied in the context of breast
cancer as more specific functional subgroups of receptor
binding which are deserving of more study since both
terms may provide insight into receptor binding activity
during breast cancer metastasis.
Our analysis also throws up new functional clusters
that should be further investigated. In C11, peptidase
activity (more specifically, serine, threonine, cysteine
and aspartic-type endopeptidase activity) is indicated asbeing associated with breast cancer. In panel C12,
the focus is on protein phosphatase regulator activity
(specifically protein phosphatase type 1 and 2A regula-
tor activity) and protein phosphatase inhibitor activity.
In panel C13, GTPase regulator activity instances are
clubbed together, including guanyl-nucleotide exchange
and Rho guanyl-nucleotide exchange factor activity.
These might provide potential candidates for target dis-
covery and therapeutics. Other functional clusters and
terms included therein can be explored for relevance, as
well as for detailed insight of specific molecular func-
tions; see Additional file 5: Table S5.
Analysis of biological processes
GO:BP analysis for Set 1 suggests that 73.5% of all pro-
teins in this study organize themselves in 539 different
process groups that participate in 205 GO:BP terms of
which only 70 have hitherto been reported in the litera-
ture related to breast cancer studies (see Table 3). Details
are included in Additional file 6: Table S6.
The present protocol thus extends earlier work in sug-
gesting novel susceptible or candidate gene targets. A
representative case-study for the third module of Set 1 is
shown in Figure 4. This contains the largest number of
interacting proteins, namely 7712 interactions among
3187 proteins (see Table 3). Of these proteins, nearly
75% form 111 process groups that participate in 96 GO:
BP terms and give 10 process clusters.
Regulation of cellular process is the largest cluster
among these contains 22 predicted terms, eleven of
which are known [57-67] to be involved in breast
cancer and is shown in Figure 4 panel C1. These are
enumerated below.
1) Signal transduction (P2).
2) Cell adhesion (P3).
3) Cell proliferation (P4).
4) Apoptosis (P6).
5) MAPK signaling pathway via the G-protein-coupled
receptor (GPCR) (P7).
6) Notch signaling pathway (P8).
7) Estrogen induced cell proliferation (P5).
8) Cell death (P22).
9) Inhibition of epidermal growth factor receptor
(EGFR) (P15) transcription.
10) Anti-apopotsis (P14).
11) Retinoblastoma cell apoptosis (P19).
In addition to these terms, cluster analysis also sug-
gests eleven additional specific novel process terms that
have not been explored so far in case of breast cancer.
It includes small GTPase mediated signal transduction
(P9), transmembrane receptor protein tyrosine kinase
signaling pathway (P11), phosphatidylinositol-mediated
Figure 4 (See legend on next page.)
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Figure 4 Network of GO:BP groups of submodular network within 3rd module of West dataset. Each submodule is highlighted by different
colors and three digit number represents the BP description of each group of proteins. Process clusters are shown in the bottom, contains process id
(#Id), GO terms followed by depth of the GO hierarchy in parenthesis, number of groups (#G), and number of proteins (#P). 23 GO terms common in
first six module, and also those represented by gene contained in more than 2 databases, represented by dotted hull. Detail of each GO:BP term is
shown in right panel. Inset represents the zoom in of a process group 3.8.3 made up of 3 overlapping and 2 independent group of proteins. Disc, ring,
and rhombus represents, GO:BP terms have already been reported in literature, newly reported GO terms and cluster component not reported in our
analysis (shown with symbol ‘+’), respectively.
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tion (P13), transforming growth factor beta receptor
signaling pathway (P16), regulation of JNK cascade (P17),
negative regulation of transforming growth factor beta
receptor signaling pathway (P18), G-protein signaling,
coupled to cAMP nucleotide second messenger (P20),
negative regulation of apoptotic process (P10), Positive
regulation of transcription, DNA dependent (P21) and
positive regulation of proteasomal ubiquitin-dependent
protein catabolic process (P23). All these processes
should be explored further to get additional insight into
the regulation of cellular process in breast cancer.
A new candidate that has become evident through the
present analysis is the Abraxas gene [68] that has two
synonymous terms, FAM175A and CCDC98. Abraxas,
which has recently been reported in breast cancer owing
to its association with BRCA1 BRCT (BRCA1 C-terminal)
repeats motif [69], links BRCA1 to a protein complex
dedicated to ubiquitin chain recognition and hydrolysis
at DNA double strand breaks, and is thus involved in
BRCA1-dependent DNA damage response [70,71]. Abraxas
and other member of this protein complex are required
for the DNA damage checkpoints and cellular resistance
to ionizing radiation (IR) in breast cancer [68]. Though
CCDC98 is present in the GAD database, the synonym-
ous term FAM175A is filtered out during gene network
construction. The gene BRCA1 expresses two proteins
P38398 and Q6IN79 in the primary network that inter-
act with themselves as well as with four other proteins
Q6UWZ7, P46736, Q96SD1 and Q9BX63 that also par-
ticipate in double-strand break repair; these are in the
secondary network. Q6UWZ7 is expressed by FAM175A:
the two-layer protocol thus throws up a potential candi-
date gene that could be used as a novel target in the
treatment of breast cancer. This also gives the motiv-
ation to explore other candidate genes included through
the secondary network construction.
The present study also finds a novel cluster, one that
has not so far been studied in breast cancer and that
appears to be worthy of further experimental investigation.
This cluster includes the following specific biological
processes: positive regulation of transcription, DNA-
dependent (P21), transcription, DNA-dependent (P62),
regulation of transcription, DNA-dependent (P64), tran-
scription from RNA polymerase II promoter (P65),regulation of transcription from RNA polymerase II pro-
moter (P66), negative regulation of transcription, DNA-
dependent (P67) as a part of gene expression (P61)
(Figure 4, panel C10).
Analysis of cellular components
The distributions of proteins at various cellular locations
in all seven modules of Set 1 are shown in Figure 5.
About 75% of the proteins organize themselves to form
434 different component submodules that are distrib-
uted across 23 different sub-cellular locations as men-
tioned in Table 3; the complete details are in Additional
file 7: Table S7.
The largest cluster corresponds to the intracellular
component (C8) (Figure 5, panel b) which appears to be
the most favorable site for breast cancer progression.
The BRCA1 gene that is involved in DNA repair is
mainly active in the intracellular subcomponent, in the
cytoplasm (C9) of breast ductal epithelial cells. Any dys-
function in BRCA1 correlates with greater risk of breast
cancer symptoms [72]. Another gene BIK, an apoptotic
inducer in breast cancer cell, also known as BCL2 inter-
acting killer performs its activity primarily at another
intracellular sub-location, the endoplasmic reticulum
(C12) [73]. Thapsigargin (TG), a highly specific inhibitor
of the endoplasmic reticulum (C12) Ca2 + −ATPase pump
and sarcoplasmic reticulum (C10), induced the apoptosis
in the breast cancer cells as a subsequent to the secondary
rise in [Ca2+] [74]. While the release of cytochrome-C
from mitochondria (C8) served as an early signalling for
the intrinsic pathway of apoptosis in breast cancer MCF-
7c3 cells [75]. Caveolin-1 (CAV1), a highly conserved
membrane-associated protein, is localized in the various
subcellular locations including endoplasmic reticulum
membrane (C7). Phosphorylation of CAV1 on Tyr-14
regulates paclitaxel-mediated apoptosis in MCF-7 breast
cancer [76]. Also, various nuclear changes, such as en-
largement, shrinkage, necrosis, vacuolation and pynknotic
nuclei (C14) have already been reported in the breast
cancer metastasis [77].
Cluster analysis also indicates more specific intracellu-
lar locations in the cytosol, mitochondrion, Golgi appar-
atus, sarcoplasmic reticulum and endoplasmic reticulum
membrane as sites wherein breast cancer activity occurs.
A recent study reports Caspase-2 releases from nucleus
Figure 5 Distribution of proteins in GO:CC terms within 7 module of West dataset. Each dot represents the sum of proteins annotated in
different class for a GO:CC term for each module, shown in different colors. Labels at the top, #Proteins, represents the cumulative sum of all the
proteins for a specific GO:CC term, whereas #Group, represents the total number of group class found in all modules. Bottom panel represents
the component clusters, where number in the parenthesis shows the level in the GO hierarchy. Disc, ring, and rhombus represents, GO:CC terms
have already been reported in literature, newly reported GO terms and cluster component not reported in our analysis, respectively.
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induction by taxanes in breast cancer cells [78]. Simi-
larly, other cellular component clusters can be explored
for the detailed analysis, as discussed in Additional file 7:
Table S7.
Our analysis of Set 2 for all three GO categories is
included in Additional file 8: Table S8, Additional file 9:
Table S9 and Additional file 10: Table S10. Results for
both the datasets are similar, in as much as the majority
of the biological activities in BP, MF, and CC are identi-
cal in both sets. This analysis thus makes it possible to
i validate domains with relevant activity in breast
cancer (as reported in literature).
ii identify new domain terms to examine details of
specific biological activity, and
iii determine important domain clusters as the site
of major biological activity.Discussion
In the past few years, the integrated analysis of gene
expression data in context of PPI has received conside-
rable attention. One objective has been to derive biologi-
cally interesting subnetworks or modules of interpretable
size from large scale PPI data [79]. Subnetwork detection,
in particular uncovering modules in the context of biology
(similar to community detection in social networks) has
received considerable attention [9,10]. In social networks
such modules are shown to have a hierarchical structure
with submodules being embedded in modules [80-82].
We have explored analogous organization principles in
breast cancer data to construct the two-layer network of
breast cancer genes and the associated proteins, using
gene expression and PPI dataset.
There are, however, caveats. Noise in the available
microarray or annotation data as well as incomplete anno-
tations can make the network reconstruction ambiguous,
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anism, in particular the combinatorics involved makes
it difficult to draw direct inferences. We have consid-
ered all currently available annotations for the given set
of proteins, but since many proteins are as yet un-
annotated, this will affect the fraction of proteins in the
largest domains and thus can alter the GO-H score for
any selected set of proteins. The protocol can be modi-
fied to include a predictive aspect by using the principle
of guilt-by association [83] in order to discover the
possible function of a protein of unknown function: if a
protein has many neighbors with a particular GO clas-
sification, it is likely to belong to that particular class as
well [84,85].
Conclusion
In summary, we have construct the two-layer “network
of networks” of breast cancer genes and associated
proteins. The breast cancer bilayer network has a hier-
archical modular structure, with sub-modules inside
modules.This structure is robust: the general topology
is unaltered even when some specific proteins are
removed (as seen when the LOO-CV protocol is imple-
mented). Alternate methods that test the stability of a
control network in comparison to networks formed
from a random collection of genes or proteins are avail-
able, but these are not applicable here since there is ex-
tensive work on breast cancer genes and networks.
Furthermore, subgroup analysis for small subgroups is
unlikely to be effective [86] and randomization changes
the overall topology of the control network and results
in essentially no overlap with the primary network; this
also reduces the probability of getting a similar progno-
sis among randomized groups.
The property of submodularity has advantages. Sub-
modules are smaller units of biological organization that
allow network abstraction at specific levels and thus
helps determine domain activity through a small number
of interacting submodular units rather than through the
hundreds or thousands of proteins in a complex net-
work. The different hub proteins within the submodules
perform specific domain activities in a coordinated man-
ner. We performed a complete ontological analysis to
determine the GO profile that is involved in breast
cancer. Some of these protein groups are involved in
multiple biological activities and also form clusters of
specific domain activities associated with various GO
terms. This division into smaller groups helps to identify
the set of proteins that participate in specific domain
activities, and can be used to examine the organization
and coordination of complex domain activities. We
have also shown that specific submodules contain more
conserved domain groups and these are assumed to be
preserved during evolution [87].The two-layer protocol allows not only the catalogue
of the (well-studied) domain activities in breast cancer
but also permits the prediction of more specific domain
activities at a lower level of the ontological hierarchy.
The analysis predicts new domain clusters which has
not been studied in the context of breast cancer, and
identifies Q6UWZ7, a protein expressed by a newly
reported breast cancer marker gene Abraxas through
the secondary network. In addition to identifying novel
domain activities, this protocol can thus also point to
new biomarkers.
Given the ever-increasing amount of interaction data
available, we expect that the two-layer approach described
herein will prove useful in ongoing efforts to explore the
protein interaction universe and understand how domain
building blocks are assembled together to perform or alter
normal activity, not only in breast cancer, but in other
complex diseases as well.Additional files
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